Kyowa Kirin said on June 26 that it has received Japanese regulatory approval for a new pen-type formulation of its anti-interleukin-17 (IL-17) receptor A antibody Lumicef (brodalumab).The newly approved Lumicef Subcutaneous Injection 210 mg Pen is a prefilled autoinjector containing…
To read the full story
Related Article
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
BUSINESS
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





